Thyrocare Technologies Ltd Share Price – NSE  / BSE

Healthcare, Small Cap

Dr. Ramesh Kinha is a healthcare and diagnostics professional with over 17 years of experience. Before joining the company, he was Group Director ? Laboratory Services at Vijaya Diagnostic Centre and has held leadership roles at Apollo Health & Lifestyle, Medall Healthcare, Metropolis Healthcare, and SRL. He holds an MBBS and an MD (Pathology), has completed senior management programs from IIM Nagpur and ISB, and is an NABL Assessor.

Thyrocare Technologies is India's first and foremost advanced fully automated laboratory chain with a strong presence PAN India. The company focuses on providing quality and affordable diagnostic services to laboratories and hospitals. Thyrocare has a quarterly active franchise count of more than 10,000 and has processed over 53.3 million diagnostic and screening investigations in Q2 FY26.

The company reported an 82% jump in consolidated net profit to Rs 47.90 crore on a 22% rise in revenue from operations to Rs 216.53 crore in Q2 FY26 over Q2 FY25.

Shares of Thyrocare Technologies shed 0.23% to Rs 441.30 on the BSE.

Powered by Capital Market - Live News

Thyrocare Technologies has allotted 10,61,07,794 equity shares of Rs 10 each under bonus issue in ratio of 2:1. Post allotment, the paid up equity share capital has increased to 15,91,61,691 equity shares of Rs 10 each.

Powered by Capital Market - Live News

Thyrocare Technologies announced that Nitin Chugh, Chief Commercial Officer and part of the Senior Management Personnel of the company has resigned with effect from 30 November 2025.

Powered by Capital Market - Live News

Docon Technologies Private Limited (?Docon?), Promoter of Thyrocare Technologies has sold 53,32,860 equity shares of the Company through market trades on 24th October 2025 for an aggregate gross consideration of Rs. 667.69 crore (rounded off), at an average price of approximately Rs. 1,252.03 per share (rounded off).

The number of shares sold constitutes approximately 10% of the total paid-up capital of the Company. Following this transaction, Docon continues to be a promoter of the Company. Post this transaction, the promoter shareholding in the Company stands reduced to 60.93% from the pre-transaction shareholding of 70.98%.

Powered by Capital Market - Live News